Vector Labs Ab00613-10.6 Anti-CD19 [FMC63], Human Fab fragment, His-Tagged, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: FMC63
Heavy Chain Modification: His-Tagged
Synonyms: B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; Leu12; T-cell surface antigen Leu-12
Amount: 200 μg
Application Codes Clone: FC; IF; FACS; IHC; IP; Depletion; In vivo
Shipping Temperature: Wet Ice
Origin Pub PMID: 9566763
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2a
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for human CD19, a 95 kDa protein expressed in the B-lymphocyte lineage.
Application Notes: FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991; PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997; PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999; PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998; PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011; PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023; PMID: 37879074).

Product Class:	Purified
Clone ID:	FMC63
Heavy Chain Modification:	His-Tagged
Synonyms:	B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; Leu12; T-cell surface antigen Leu-12
Amount:	200 μg
Application Codes Clone:	FC; IF; FACS; IHC; IP; Depletion; In vivo
Shipping Temperature:	Wet Ice
Origin Pub PMID:	9566763
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2a
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for human CD19, a 95 kDa protein expressed in the B-lymphocyte lineage.
Application Notes:	FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991; PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997; PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999; PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998; PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011; PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023; PMID: 37879074).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews